Absci (ABSI) Times Interest Earned (2020 - 2026)
Absci (ABSI) posted Times Interest Earned of -$3.45 for Q1 2026, up 99.68% sequentially from -$1070.4 in Q4 2025, and up 27.9% YoY from -$2.69 in Q1 2025.
Absci (ABSI) Times Interest Earned (2020 - 2026) Analysis & Trends
Absci has reported Times Interest Earned for 7 years, with the latest figure at -$3.45 in Q1 2026.
- Quarterly Times Interest Earned rose 27.9% year-over-year to -$3.45 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.79 (up 29.28% YoY) and the FY2025 annual result came in at -$1.13, up 18.85% from the prior year.
- Times Interest Earned rose to -$3.45 in Q1 2026 per ABSI's latest filing, from -$1070.4 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.42 in Q1 2024 and troughed at -$1070.4 in Q4 2025.
- A 5-year average of -$93.59 and a median of -$4.78 in 2025 frame the typical range for Times Interest Earned.
- The widest YoY moves for Times Interest Earned: up 97.23% in 2022, down 1495.07% in 2022.
- Over 5 years, Times Interest Earned stood at -$36.24 in 2022, then slumped by 316.22% to -$150.85 in 2023, then tumbled by 81.08% to -$273.16 in 2024, then tumbled by 291.86% to -$1070.4 in 2025, then soared by 99.68% to -$3.45 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$3.45, -$1070.4, and -$3.08 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - | -0.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.18 |
| Mar 31, 2026 | -3.45 |
| Dec 31, 2025 | -1,070.38 |
| Sep 30, 2025 | -3.08 |
| Jun 30, 2025 | -5.56 |
| Mar 31, 2025 | -4.78 |
| Dec 31, 2024 | -273.16 |
| Sep 30, 2024 | -1.34 |
| Jun 30, 2024 | -2.08 |
| Mar 31, 2024 | -0.42 |
| Dec 31, 2023 | -150.85 |
| Sep 30, 2023 | -8.13 |
| Jun 30, 2023 | -14.99 |
| Mar 31, 2023 | -8.54 |
| Dec 31, 2022 | -36.24 |
| Sep 30, 2022 | -3.85 |
| Jun 30, 2022 | -3.47 |
| Mar 31, 2022 | -0.68 |
| Dec 31, 2021 | -131.28 |
| Sep 30, 2021 | -0.30 |